2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2289

Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells
Abstract Number: 465

Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review
Abstract Number: 373

Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis
Abstract Number: 2326

Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Abstract Number: 2587

Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis
Abstract Number: 1583

Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus
Abstract Number: 1624

Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Abstract Number: 2823

Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Abstract Number: 300

Proliferative Globular Synovitis, an Ultrasound Pattern Associated with Seropositive Rheumatoid Arthritis
Abstract Number: 2454

PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Abstract Number: 1040

Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity
Abstract Number: 2882

Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Abstract Number: 2567

Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Abstract Number: 596

Prostaglandin Receptor EP4 Drives Pathogenic Th17 Cell Development in Ankylosing Spondylitis and Is a New Marker of Disease Activity
Abstract Number: 1973

Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].